Advert Novo Nordisk

Promotion of Saxenda

For promoting Saxenda (liraglutide) at a fertility conference without ensuring that materials for health professionals (in addition to references in the prescribing information) and patients made available on a Novo Nordisk exhibition stand made it clear that Saxenda was not to be used in pregnancy, those wishing to become pregnant and those breast feeding, and for failing to be able to show that representatives were trained and their briefing was certified, Novo Nordisk was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 7.2 - Failing to reflect the current warnings and potential risks set out in the summary of product characteristics with respect to the safety of the medicine in pregnancy, those wishing to become pregnant and those breast feeding

Clause 9.1 - Failing to maintain high standards

Clause 15.1 - Failure to be able to show that representatives had been adequately trained to promote Saxenda within the fertility area

Clause 15.9 - Failure to certify a verbal briefing given to representatives

Clause 26.2 - Providing misleading information for patients

 

Feb Advert 2021